ASX-listed clinical stage oncology company Prescient Therapeutics Limited (ASX:PTX) revealed that the Company has amended a key term in its collaboration arrangement with Carina Biotech.
PTX disclosed that it has negotiated to be the complete owner of any new IP resulting from collaboration. PTX would carry the sole cost of the project, which is within its current budget.
Post announcement shares of PTX climbed by 6.383% to $0.050 on 11 May 2020 (at AEST 11:17 AM).
Disclaimer
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
